250 related articles for article (PubMed ID: 15661905)
1. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.
Chang CC; Campoli M; Restifo NP; Wang X; Ferrone S
J Immunol; 2005 Feb; 174(3):1462-71. PubMed ID: 15661905
[TBL] [Abstract][Full Text] [Related]
2. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.
Wang Z; Marincola FM; Rivoltini L; Parmiani G; Ferrone S
J Exp Med; 1999 Jul; 190(2):205-15. PubMed ID: 10432284
[TBL] [Abstract][Full Text] [Related]
3. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Hicklin DJ; Wang Z; Arienti F; Rivoltini L; Parmiani G; Ferrone S
J Clin Invest; 1998 Jun; 101(12):2720-9. PubMed ID: 9637706
[TBL] [Abstract][Full Text] [Related]
4. Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules.
Martayan A; Fraioli R; Giorda E; Setini A; Ciccarelli G; Delfino L; Ferrara GB; Giacomini P
Br J Cancer; 1999 May; 80(5-6):639-49. PubMed ID: 10360639
[TBL] [Abstract][Full Text] [Related]
5. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.
Chang CC; Ogino T; Mullins DW; Oliver JL; Yamshchikov GV; Bandoh N; Slingluff CL; Ferrone S
J Biol Chem; 2006 Jul; 281(27):18763-73. PubMed ID: 16648140
[TBL] [Abstract][Full Text] [Related]
6. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
7. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29.
Wang Z; Seliger B; Mike N; Momburg F; Knuth A; Ferrone S
Cancer Res; 1998 May; 58(10):2149-57. PubMed ID: 9605759
[TBL] [Abstract][Full Text] [Related]
9. Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.
Martayan A; Sibilio L; Tremante E; Lo Monaco E; Mulder A; Fruci D; Cova A; Rivoltini L; Giacomini P
J Immunol; 2009 Mar; 182(6):3609-17. PubMed ID: 19265139
[TBL] [Abstract][Full Text] [Related]
10. Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance.
Hicklin DJ; Dellaratta DV; Kishore R; Liang B; Kageshita T; Ferrone S
Melanoma Res; 1997 Aug; 7 Suppl 2():S67-74. PubMed ID: 9578419
[TBL] [Abstract][Full Text] [Related]
11. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression.
Wang Z; Margulies L; Hicklin DJ; Ferrone S
Tissue Antigens; 1996 May; 47(5):382-90. PubMed ID: 8795138
[TBL] [Abstract][Full Text] [Related]
12. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Restifo NP; Marincola FM; Kawakami Y; Taubenberger J; Yannelli JR; Rosenberg SA
J Natl Cancer Inst; 1996 Jan; 88(2):100-8. PubMed ID: 8537970
[TBL] [Abstract][Full Text] [Related]
13. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
14. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
15. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.
Carretero R; Wang E; Rodriguez AI; Reinboth J; Ascierto ML; Engle AM; Liu H; Camacho FM; Marincola FM; Garrido F; Cabrera T
Int J Cancer; 2012 Jul; 131(2):387-95. PubMed ID: 21964766
[TBL] [Abstract][Full Text] [Related]
16. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?
Atkins D; Ferrone S; Schmahl GE; Störkel S; Seliger B
J Urol; 2004 Feb; 171(2 Pt 1):885-9. PubMed ID: 14713847
[TBL] [Abstract][Full Text] [Related]
18. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
Facoetti A; Nano R; Zelini P; Morbini P; Benericetti E; Ceroni M; Campoli M; Ferrone S
Clin Cancer Res; 2005 Dec; 11(23):8304-11. PubMed ID: 16322289
[TBL] [Abstract][Full Text] [Related]
19. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
Int J Cancer; 2011 Jan; 128(2):390-401. PubMed ID: 20715101
[TBL] [Abstract][Full Text] [Related]
20. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
